Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Quality Improvement Initiatives to Improve Transfusion Safety and Efficiency for Patients Receiving Daratumumab

Richard Curtis Godby, MD, Tammy Gray, BS, Hollie Christopher, BS, MLS, Lance A. Williams, III, MD, Marisa B. Marques, MD

Blood (2019) 134 (Supplement_1): 2100.

https://doi.org/10.1182/blood-2019-126958

Published: 2019

Journal Articles

Phosphorus Levels in Iron Deficient Children Treated with Ferric Carboxymaltose

Susan Kirk, PA-C, Donald Mahoney, MD, Melanie Brooke Bernhardt, PharmD, Jacquelyn M. Powers, MD,MSc

Blood (2019) 134 (Supplement_1): 2240.

https://doi.org/10.1182/blood-2019-129159

Published: 2019

Journal Articles

A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Ian Gould, PhD, Jan Bassali, PharmD, Jyotsna Mehta, Jatin Shah, MD, Dee Dee Mladsi, BA

Blood (2019) 134 (Supplement_1): 5824.

https://doi.org/10.1182/blood-2019-125997

Published: 2019

Journal Articles

Realized and Projected Cost Savings from the Introduction of Generic Imatinib, with Minimal Additional Savings to Payers through Formulary Management

Lisa Bloudek, John Brokars, MS, Campbell David, PharmD, MS, Dinara Makenbaeva, MD MBA

Blood (2018) 132 (Supplement 1): 3533.

https://doi.org/10.1182/blood-2018-99-111966

Published: 2018

Journal Articles

Health Care Utilization and Costs Among Patients with Chronic Myeloid Leukemia Using Tyrosine Kinase Inhibitors

Joanna C Huang, PharmD, Sudeep Karve, PhD, Sanchita Porwal, BS, Kushan Thakkar, MS, Thomas Marshall, PharmD, MS, Tanja Rosenberg, MD

Blood (2018) 132 (Supplement 1): 3537.

https://doi.org/10.1182/blood-2018-99-113809

Published: 2018

Journal Articles

The New Landscape of Checkpoint Inhibitors in China

Chien-Shing Chen, MD PhD

Blood (2018) 132 (Supplement 1): 5855.

https://doi.org/10.1182/blood-2018-99-111666

Published: 2018

Journal Articles

Availability of ATRA, Blood BANK Support, Treatment Protocols and Hematologists/Oncologists for Management of APL in Two States (MICHIGAN AND LOUSIANA)

Sheldon Bolds, Shruthi M.K Hassan, Catherine R. Caprara, MSN, NP, Stephanie Debragga, Kathryn Sarah Simon, PA-C, Prachi Kharkhanis, Arpita Gandhi, Martha L. Arellano, MD, Anand Jillella, MD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 5620.

https://doi.org/10.1182/blood.V130.Suppl_1.5620.5620

Published: 2017

Journal Articles

Budget Impact Analysis of Switching Chemotherapy Patients Using Granulocyte Colony-Stimulating Factors (G-CSFs) from Pegfilgrastim to Short-Acting G-CSFs in the United States

Elizabeth James, Holly Trautman, Erika Szabo, Boxiong Tang, MD PhD

Blood (2017) 130 (Supplement 1): 4668.

https://doi.org/10.1182/blood.V130.Suppl_1.4668.4668

Published: 2017

Journal Articles

Budget Impact Analysis of Treating Chemotherapy Patients with Patient-Administered Tbo-Filgrastim, Filgrastim-Sndz, and Filgrastim in the United States

Holly Trautman, Erika Szabo, Francesco Lo-Coco, Elizabeth James, Susan Gabriel, Jifang Zhou, Ashutosh Pathak, Boxiong Tang

Blood (2016) 128 (22): 4786.

https://doi.org/10.1182/blood.V128.22.4786.4786

Published: 2016

Journal Articles

Budget Impact Analysis of Introducing Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A US Payer Perspective

Ravi Potluri, Hitesh Bhandari, Sandip Ranjan, Clara Chen, PhD MS

Blood (2016) 128 (22): 2363.

https://doi.org/10.1182/blood.V128.22.2363.2363

Published: 2016

Journal Articles

ATRA Availability on Formulary for the Treatment of APL Across Hospitals in the State of Georgia

Sarah Wheeler, PharmD, Harika Puttagunta, MD, Minal Surati, PharmD, Elyse Panjic, PharmD, Arpita Shah, PharmD, Martha Arellano, MD, Anand Jillella, MD, Vamsi K Kota, MD

Blood (2015) 126 (23): 4924.

https://doi.org/10.1182/blood.V126.23.4924.4924

Published: 2015

Journal Articles

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

Richard A. Larson, Rena Conti, PhD, William V. Padula, PhD, Jane F. Apperley, Michele Baccarani, MD, Ekkehard Eigendorff, MD, Francois Guilhot, MD, Joelle Guilhot, PhD, Francois-Xavier Mahon, MD PhD, Giovanni Martinelli, MD, Jiri Mayer, Prof., MD PhD, Martin C. Mueller, Dietger Niederwieser, MD, Susanne Saussele, MD, Charles A. Schiffer, MD, Richard T. Silver, MD, Bengt Simonsson, MD PhD, Rudiger Hehlmann, MD

Blood (2014) 124 (21): 738.

https://doi.org/10.1182/blood.V124.21.738.738

Published: 2014

Journal Articles

Clinical Availability of All-Trans Retinoic Acid (ATRA) for Patients with Suspected Acute Promyelocytic Leukemia – Why National Guidelines May Not be Followed

Nagendra Mogasala, Sumana Devata, MD, Anthony Perissinotti, PharmD, Dale Bixby, MD PhD

Blood (2014) 124 (21): 2297.

https://doi.org/10.1182/blood.V124.21.2297.2297

Published: 2014

Journal Articles

Rivaroxaban Versus Low Molecular Weight Heparin For The Prevention Of Venous Thromboembolism After Orthopedic Surgery: A Population-Based Study

Alejandro Lazo-Langner, MD, MSc, Jamie L. Fleet, BHSc, Eric McArthur, MSc, Amit X. Garg, MD PhD

Blood (2013) 122 (21): 215.

https://doi.org/10.1182/blood.V122.21.215.215

Published: 2013

Journal Articles

Effectiveness and Cost of Rituximab for CLL in the Province of Manitoba Prior to Its Approval As Part of First Line Treatment

Pamela Skrabek, FRCPC, Rajat Kumar, FRCPC, James B Johnston, MD, Joseph Baptiste, MD, Bernie Lozar, Scott Streilein, Venetia Bourrier, FCSHP, Sri Navaratnam, FRCPC

Blood (2012) 120 (21): 4701.

https://doi.org/10.1182/blood.V120.21.4701.4701

Published: 2012

Journal Articles

Pharmacologic Prophylaxis for Venous Thromboembolism Among Hospitalized Patients with Acute Medical Illness: An Electronic Medical Records Study

Marc B Rosenman, MD, Xianchen Liu, MD, PhD, Hemant Phatak, PhD, Amy Qi, Evgenia Teal, Daniel Nisi, Larry Z Liu, MD, PhD, Eduardo Ramacciotti, M.D., Ph.D.

Blood (2011) 118 (21): 2074.

https://doi.org/10.1182/blood.V118.21.2074.2074

Published: 2011

Journal Articles

Hemolytic Anemia Following Intravenous Immunoglobulin Administration: A Cluster of Suspected Cases

Jonathan S. Bleeker, MD, Elizabeth A. Jaben, MD, Eapen K. Jacob, MD, James R. Stubbs, MD, Brenda J. Bendix, MLS(ASCP)SBB, Dennis A. Gastineau, MD, Aneel A. Ashrani, MD, MS

Blood (2011) 118 (21): 4332.

https://doi.org/10.1182/blood.V118.21.4332.4332

Published: 2011

Journal Articles

Physician Perceptions and Preferences in the Treatment of Acquired Immunodeficiency Syndrome (AIDS)-Related Lymphoma (ARL).

Matthew C. Cheung, MD, Mona R. Loutfy, MD, MPH, Heather A. Leitch, MD, PhD, Rena Buckstein, MD, Kevin R. Imrie

Blood (2006) 108 (11): 3331.

https://doi.org/10.1182/blood.V108.11.3331.3331

Published: 2006

NARROW

Quality Improvement Initiatives to Improve Transfusion Safety and Efficiency for Patients Receiving Daratumumab

Phosphorus Levels in Iron Deficient Children Treated with Ferric Carboxymaltose

A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Realized and Projected Cost Savings from the Introduction of Generic Imatinib, with Minimal Additional Savings to Payers through Formulary Management

Health Care Utilization and Costs Among Patients with Chronic Myeloid Leukemia Using Tyrosine Kinase Inhibitors

The New Landscape of Checkpoint Inhibitors in China

Availability of ATRA, Blood BANK Support, Treatment Protocols and Hematologists/Oncologists for Management of APL in Two States (MICHIGAN AND LOUSIANA)

Budget Impact Analysis of Switching Chemotherapy Patients Using Granulocyte Colony-Stimulating Factors (G-CSFs) from Pegfilgrastim to Short-Acting G-CSFs in the United States

Budget Impact Analysis of Treating Chemotherapy Patients with Patient-Administered Tbo-Filgrastim, Filgrastim-Sndz, and Filgrastim in the United States

Budget Impact Analysis of Introducing Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A US Payer Perspective

ATRA Availability on Formulary for the Treatment of APL Across Hospitals in the State of Georgia

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

Clinical Availability of All-Trans Retinoic Acid (ATRA) for Patients with Suspected Acute Promyelocytic Leukemia – Why National Guidelines May Not be Followed

Rivaroxaban Versus Low Molecular Weight Heparin For The Prevention Of Venous Thromboembolism After Orthopedic Surgery: A Population-Based Study

Effectiveness and Cost of Rituximab for CLL in the Province of Manitoba Prior to Its Approval As Part of First Line Treatment

Pharmacologic Prophylaxis for Venous Thromboembolism Among Hospitalized Patients with Acute Medical Illness: An Electronic Medical Records Study

Hemolytic Anemia Following Intravenous Immunoglobulin Administration: A Cluster of Suspected Cases

Physician Perceptions and Preferences in the Treatment of Acquired Immunodeficiency Syndrome (AIDS)-Related Lymphoma (ARL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only